Large-scale testing (Phase 3)Study completedNCT02280044
What this trial is testing
Efficacy of Rifaximin in Preventing Campylobacteriosis
Who this might be right for
DysenteryDiarrheaEnteric Campylobacteriosis
Johns Hopkins Bloomberg School of Public Health 30